EA000531B1 - Активное вещество при производстве фармацевтического препарата для лечения травматического повреждения головного мозга - Google Patents

Активное вещество при производстве фармацевтического препарата для лечения травматического повреждения головного мозга Download PDF

Info

Publication number
EA000531B1
EA000531B1 EA199800434A EA199800434A EA000531B1 EA 000531 B1 EA000531 B1 EA 000531B1 EA 199800434 A EA199800434 A EA 199800434A EA 199800434 A EA199800434 A EA 199800434A EA 000531 B1 EA000531 B1 EA 000531B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical preparation
treatment
traumatic brain
active substance
cerebral
Prior art date
Application number
EA199800434A
Other languages
English (en)
Russian (ru)
Other versions
EA199800434A1 (ru
Inventor
Брайан Р. Пайк
Original Assignee
Х.Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х.Лундбекк А/С filed Critical Х.Лундбекк А/С
Publication of EA199800434A1 publication Critical patent/EA199800434A1/ru
Publication of EA000531B1 publication Critical patent/EA000531B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA199800434A 1995-11-06 1996-11-05 Активное вещество при производстве фармацевтического препарата для лечения травматического повреждения головного мозга EA000531B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK123295 1995-11-06
PCT/DK1996/000458 WO1997017074A1 (en) 1995-11-06 1996-11-05 Treatment of traumatic brain injury

Publications (2)

Publication Number Publication Date
EA199800434A1 EA199800434A1 (ru) 1998-10-29
EA000531B1 true EA000531B1 (ru) 1999-10-28

Family

ID=8102484

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199800434A EA000531B1 (ru) 1995-11-06 1996-11-05 Активное вещество при производстве фармацевтического препарата для лечения травматического повреждения головного мозга

Country Status (18)

Country Link
EP (1) EP0866706A1 (de)
JP (1) JPH11514654A (de)
KR (1) KR19990067353A (de)
AU (1) AU706594B2 (de)
BG (1) BG63150B1 (de)
BR (1) BR9611396A (de)
CA (1) CA2234824A1 (de)
CZ (1) CZ287441B6 (de)
EA (1) EA000531B1 (de)
HU (1) HUP9901051A2 (de)
IS (1) IS4726A (de)
NO (1) NO982036L (de)
NZ (1) NZ321546A (de)
PL (1) PL326490A1 (de)
SK (1) SK58198A3 (de)
TR (1) TR199800801T2 (de)
WO (1) WO1997017074A1 (de)
ZA (1) ZA969320B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013096A1 (es) * 1997-07-01 2000-12-13 Lundbeck & Co As H Sal de adicion de acido maleico de 5-(2-etil-2-h-tetrazol-5-il)-1-metil- 1,2,3,6-tetrahidropiridina, composicion farmaceutica que la contiene, su usoen terapia y metodo de preparacion de la misma.
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5330994A (en) * 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives

Also Published As

Publication number Publication date
CA2234824A1 (en) 1997-05-15
ZA969320B (en) 1997-05-30
JPH11514654A (ja) 1999-12-14
PL326490A1 (en) 1998-09-28
BR9611396A (pt) 1999-07-13
EP0866706A1 (de) 1998-09-30
EA199800434A1 (ru) 1998-10-29
AU706594B2 (en) 1999-06-17
NZ321546A (en) 2000-12-22
CZ138998A3 (cs) 1998-10-14
HUP9901051A2 (hu) 2000-03-28
SK58198A3 (en) 1998-10-07
NO982036D0 (no) 1998-05-05
WO1997017074A1 (en) 1997-05-15
MX9803432A (es) 1998-09-30
TR199800801T2 (xx) 1998-08-21
NO982036L (no) 1998-06-25
IS4726A (is) 1998-04-27
CZ287441B6 (en) 2000-11-15
BG63150B1 (bg) 2001-05-31
AU7490096A (en) 1997-05-29
KR19990067353A (ko) 1999-08-16
BG102480A (en) 1999-01-29

Similar Documents

Publication Publication Date Title
KR100197452B1 (ko) 구토 치료를 위한 nk-1 수용체 길항제 및 5ht3 수용체 길항제
US6306904B1 (en) Antihistaminic/antitussive compositions
US20040234593A1 (en) Diphenhydramine tannate compositions and methods of use
SK4862000A3 (en) The use of 5-ht3 receptor antagonists
DE3650733T2 (de) Pharmazeutische Zubereitungen und medizinische Verwendungen von Dioxopiperidinderivaten, insbesondere als Verstärker der Immunantwort sowie als antivirale und antibakterielle Wirkstoffe
HU202108B (en) Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
SK282403B6 (sk) 2,4-Disulfonyl-alfa-fenyl-terc-butylnitrón alebo jeho farmaceuticky prijateľná soľ, farmaceutický prostriedok s ich obsahom a ich použitie
US20010006972A1 (en) Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
US6297262B1 (en) Treatment of schizophrenia and psychosis
EP0873753A1 (de) Verwendung von NK-1 Rezeptor Antagonisten zur Herstellung eines Medikaments für die Behandlung von Darmreizungssyndrom
JPS63185927A (ja) 薬物中毒治療のための医薬
EA000531B1 (ru) Активное вещество при производстве фармацевтического препарата для лечения травматического повреждения головного мозга
AU764304B2 (en) Use of saredutant and of its pharmaceutically acceptable salts for the preparation of medicinal products that are useful in the treatment or prevention of major depressive disorders
CA2126678A1 (en) Use of spiperone or spiperone derivatives as immunosuppressant agents
US11883385B2 (en) Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome
US6610720B2 (en) Method for treating or preventing emesis
CA2453256A1 (en) Diphenhydramine tannate compositions and methods of use
EP0690715B1 (de) Topische und systemische anwendung von buspiron und seinen derivaten zur behandlung von pathologischen zuständen, die mit immunantworten verbunden sind
DE3904795C2 (de) Pharmazeutisches Präparat und dessen Verwendung
RU2780646C1 (ru) Новая кристаллическая форма 7-бром-1-(гидразинокарбонил)метил-5-фенил-1,2-дигидро-3h-1,4-бензодиазепин-2-она и ее фармацевтическое применение
US3743746A (en) Process of treating peptic ulcer with a non-anticholinergic agent
US20030166667A1 (en) Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
CZ2001150A3 (cs) Lék pro léčbu psychóz nebo jiných neuropsychiatrických příznaků u pacientů s Alzheimerovou chorobou
MXPA98003432A (en) Treatment of traumat cerebral damage
US4721714A (en) Anti-vertigo drug

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU